ALGS250321P2500
- 0.00
- 0.000.00%
Aligos Therapeutics Newsroom
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 17% Last Week
NASDAQ New 52-Week Highs And Lows
Express News | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics to Present at Investor Conferences in December
Express News | Adage Capital Management, L.p. Reports 7.12% Passive Stake in Aligos Therapeutics as of Sept 30 - SEC Filing
Express News | Aligos Therapeutics Shares Resume Trade Following Circuit Breaker Halt, Stock Now Up 60%
Express News | Aligos Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Revenue Results. HC Wainwright & Co. Reiterated a Buy Rating on the Stock
Aligos Therapeutics Participates in a Conference Call With Jefferies
Aligos Therapeutics Analyst Ratings
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $75
Aligos Therapeutics Reports Q3 EPS ($3.07), Consensus ($2.16)
Express News | Aligos Therapeutics Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing
Express News | Aligos Therapeutics Inc - Cash Balance Provides Sufficient Cash to Fund Planned Operations Through End of 2025
Aligos Therapeutics | 10-Q: Q3 2024 Earnings Report
Aligos Therapeutics | 8-K: Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Aligos Therapeutics 3Q Loss/Shr $3.07 >ALGS
Earnings Preview: ALGS to Report Financial Results Post-market on November 06
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
Express News | HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $75 Price Target